Opinion: Launch prices: tackling the next drug pricing challenge
The passage of the Inflation Reduction Act brings a new era to drug pricing in the United States. After decades of being an outlier, it now joins every other developed nation in having the federal government engaged in negotiating drug pricing.
The pharmaceutical industry will continue its fight to blunt the implementation of the law, but in coming years Medicare prices for a limited number of high-cost medications will be lowered, with new prices established either through steep discounts off the average price in the private insurance market or by considerations of comparative effectiveness and other factors within a broader “negotiation” process.
Read Original Article: Opinion: Launch prices: tackling the next drug pricing challenge »
